Latest Breaking News On - Stable disease - Page 1 : comparemela.com

Biodexa Pharmaceuticals PLC Announces Positive Statistically Significant Phase 2 Clinical Trial Results of eRapa? in Familial Adenomatous Polyposis Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting

Biodexa Pharmaceuticals PLC announced that results of a Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis are scheduled for presentation at the prestigious 2024 Digestive Disease.

United statesDc carol burkeBiodexa pharmaceuticalsResearch institute of texasFamilial adenomatous polyposisDisease weekPrincipal investigatorCancer preventionResearch instituteProgressive diseaseStable diseasePartial responseAdverse events

Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting

Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomCarol burkeTexas legislatureBiodexa pharmaceuticalsEmtora biosciences incResearch institute of texasStatistically significant phaseTrial resultsFamilial adenomatous polyposisDisease week annualDisease weekPrincipal investigatorCancer preventionResearch instituteProgressive disease

Pacylex CEO reveals Zelenirstat phase one results

Pacylex Pharmaceuticals Inc. has announced the presentation of phase 1 safety and efficacy findings for small molecule drug zelenirstat for cancer treatment.

United statesMichael weickertPacylex pharmaceuticalsWorld orphan drug congress united statesStable diseaseMyeloid leukemiaAcute myeloid leukemiaFast trackNew drugDrink administrationPacylex pharmaceuticalClinical developmentAtient centricityPis active pharmaceutical ingredientsHasei iiClinical trials

Pacylex Pharmaceuticals Announces First Patient Dosed in a Phase 2a Study of zelenirstat in Patients with Refractory Metastatic Colorectal Cancer

Pacylex Pharmaceuticals Announces First Patient Dosed in a Phase 2a Study of zelenirstat in Patients with Refractory Metastatic Colorectal Cancer
torontotelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from torontotelegraph.com Daily Mail and Mail on Sunday newspapers.

Pacylex pharmaceuticals incCure cancer foundationPacylex pharmaceuticalsReportable incUs department of defenseStable diseaseHodgkin lymphomaOrphan drug designationFast track designation

PDCline Pharma presents interim clinical results from last cohort of patients in phase I/II trial with PDClung01 cancer vaccine

PDC*line Pharma presents interim clinical results from last cohort of patients in phase I/II trial with PDC*lung01 cancer vaccine
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesRegion flamandeEric haliouaJohan vansteenkisteMenafn andrew lloyd associates intermediaryAmerican association for cancer researchNon small cell lung cancerAmerican associationCancer researchAnnual meetingLow doseHigh doseObjective response rateProgression free survivalAdverse eventsPartial response